prostate cancer with bone metastases
Conditions
Interventions
None listed
Sponsors
Yokohama City University Medical Center,
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Physician determined that the patient has ability to understand the trial. 2.Patient has signed the Informed Consent Form. 3.Histologically confirmed prostate cancer. 4.With bone metastases on bone scan. 5.Bone metastatic prostate cancer who had not previously received hormone therapy. 6.Patient who plan to undergo hormon therapy. 7.Patient who don't have a cancer except prostate cancer within 5 years before registration. 8.ECOG Performance Status 0-2 9.Patient must be 20 years or older at the time of Informed Consent. 10.Life expectancy>=6months at the time of Informed Consent.
Exclusion criteria
Exclusion criteria: 1.Patient has active other cancers. 2.Patient has history of the severe hyper-sensitivity drug reaction. 3.Patient has severe disease. 4.Patient has disease which is not controlled properly in accordance with the protocol. 5.Physician determined that the patient was not appropriate as a candidate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival Time to initiation of subsequent antineoplastic therapy Three year progression free survival rates Three year overall survival rates Rates of initiation of subsequent antineoplastic therapy within three years | — |
Countries
Japan
Contacts
Public ContactYasuhide Miyoshi
Yokohama City University Medical Center Department of Urology and Renal Transplantation
Outcome results
None listed